Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William C Gerth

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Kidney International. Supplement|November 2, 2002
Losartan reduces the burden and cost of ESRD: public health implications from the RENAAL study for the European UnionWilliam C Gerth, Giuseppi Remuzzi, GianCarlo Viberti, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|March 14, 2007
Pharmacoeconomic analysis of caspofungin versus liposomal amphotericin B as empirical antifungal therapy for neutropenic feverJohn R Wingard, Helen L Leather, Craig A Wood, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 14, 2006
Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countriesAndrew J Ullmann, Miguel A Sanz, Andrea Tramarin, et al.
Pharmacoeconomics|June 10, 2006
The impact of losartan on the lifetime incidence of end-stage renal disease and costs in patients with type 2 diabetes and nephropathyGeorge W Carides, Shahnaz Shahinfar, Erik J Dasbach, et al.
Diabetes Care|March 1, 2003
Losartan reduces the costs associated with diabetic end-stage renal disease: the RENAAL study economic evaluationWilliam H Herman, Shahnaz Shahinfar, George W Carides, et al.
The Journal of Antimicrobial Chemotherapy|April 6, 2006
Treatment outcomes in patients receiving conventional amphotericin B therapy: a prospective multicentre study in TaiwanChien-Yuan Chen, Ritesh N Kumar, Yin-Hsun Feng, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Kidney International. Supplement|November 2, 2002
Losartan reduces the burden and cost of ESRD: public health implications from the RENAAL study for the European UnionWilliam C Gerth, Giuseppi Remuzzi, GianCarlo Viberti, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|March 14, 2007
Pharmacoeconomic analysis of caspofungin versus liposomal amphotericin B as empirical antifungal therapy for neutropenic feverJohn R Wingard, Helen L Leather, Craig A Wood, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 14, 2006
Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countriesAndrew J Ullmann, Miguel A Sanz, Andrea Tramarin, et al.
Pharmacoeconomics|June 10, 2006
The impact of losartan on the lifetime incidence of end-stage renal disease and costs in patients with type 2 diabetes and nephropathyGeorge W Carides, Shahnaz Shahinfar, Erik J Dasbach, et al.
Diabetes Care|March 1, 2003
Losartan reduces the costs associated with diabetic end-stage renal disease: the RENAAL study economic evaluationWilliam H Herman, Shahnaz Shahinfar, George W Carides, et al.
The Journal of Antimicrobial Chemotherapy|April 6, 2006
Treatment outcomes in patients receiving conventional amphotericin B therapy: a prospective multicentre study in TaiwanChien-Yuan Chen, Ritesh N Kumar, Yin-Hsun Feng, et al.
Pageof 2